Our Healthcare News

EUSA Pharma Appoints Lee Morley Chief Executive & Industry Veteran Goran Ando to Board of Directors

Hemel Hempstead, United Kingdom – – EUSA Pharma (EUSA), a recently-established profitable specialty pharmaceutical company with global reach, today announced the appointment of Lee Morley…  

Apr 21 2015

EUSA Pharma Spins Out of Jazz Pharma With Backing from Essex Woodlands

HEMEL HEMPSTEAD, United Kingdom—After completing a $700 million deal to sell EUSA Pharma Inc. to Jazz Pharmaceuticals PLC in 2012, Essex Woodlands has teamed up…  

Mar 24 2015

EUSA Pharma Successfully Launches as an Independent Profitable Pharmaceutical Business

Hemel Hempstead, United Kingdom –– EUSA Pharma (EUSA), a newly-established profitable specialty pharmaceutical business with global reach, today announced its official launch following the acquisition…  

Mar 23 2015

Entellus Medical Announces Fourth Quarter and Full Year 2014 Financial Results

PLYMOUTH, Minnesota—Entellus Medical, Inc. (“Entellus Medical” or the “Company”) (NASDAQ: ENTL), a medical technology company focused on the design, development and commercialization of products for…  

Mar 17 2015

Open Monoclonal Technology Announces OmniAb Alliance with Celgene

PALO ALTO, California—Open Monoclonal Technology, Inc. (OMT) today announced a license that provides Celgene Corporation (Celgene) with unlimited access to OMT’s proprietary OmniRat®, OmniMouse® and 

Mar 10 2015

Targacept and Catalyst Biosciences Enter Definitive Merger Agreement

WINSTON SALEM, North Carolina and SOUTH SAN FRANCISCO, California –– Targacept, Inc. (NASDAQ: TRGT) and Catalyst Biosciences, Inc., a privately held biopharmaceutical company, jointly announced…  

Mar 05 2015

Entellus Medical, Inc. Announces Pricing of Initial Public Offering

PLYMOUTH, Minnesota—Entellus Medical, Inc., a medical technology company focused on products for the minimally invasive treatment of chronic and recurrent sinusitis patients in the physician…  

Jan 28 2015

Abiomed Receives FDA HDE Approval for the Impella RP

DANVERS, Massachusetts –  Abiomed Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced that the Impella RP® (Right Percutaneous) System has…  

Jan 27 2015

Revance Therapeutics Announces Publication of Positive Results from RT002 Phase 1/2 Study

NEWARK, California—(GLOBE NEWSWIRE)—Revance Therapeutics, Inc. (Nasdaq:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for the use in aesthetic and therapeutic indications, today announced publication…  

Jan 08 2015